[{"id":"e264a041-42a7-43c6-8cea-b309a736c283","acronym":"","url":"https://clinicaltrials.gov/study/NCT05101564","created_at":"2021-11-01T11:52:59.476Z","updated_at":"2024-07-02T16:35:06.853Z","phase":"Phase 2","brief_title":"Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer","source_id_and_acronym":"NCT05101564","lead_sponsor":"Stanford University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • fulvestrant • Truseltiq (infigratinib) • letrozole • zotatifin (eFT226) • amcenestrant (SAR439859) • Soltamox (tamoxifen citrate)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 03/20/2023","start_date":" 03/20/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-04-30"},{"id":"af3308c0-744c-4b7e-92d9-8816339110ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT05510427","created_at":"2022-08-22T13:04:20.402Z","updated_at":"2024-07-02T16:35:40.025Z","phase":"Phase 1","brief_title":"Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification","source_id_and_acronym":"NCT05510427","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FGFR2 • CD4","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Truseltiq (infigratinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/07/2023","start_date":" 08/07/2023","primary_txt":" Primary completion: 08/07/2023","primary_completion_date":" 08/07/2023","study_txt":" Completion: 08/07/2023","study_completion_date":" 08/07/2023","last_update_posted":"2023-08-15"},{"id":"484ddfbb-7589-4666-ae34-6a1cb206f2f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05019794","created_at":"2021-08-25T14:53:06.567Z","updated_at":"2024-07-02T16:36:08.254Z","phase":"Phase 2a","brief_title":"Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations","source_id_and_acronym":"NCT05019794","lead_sponsor":"LianBio LLC","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 amplification","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truseltiq (infigratinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 05/13/2020","start_date":" 05/13/2020","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2022-06-27"},{"id":"9b359a40-04d8-4213-8647-647643b00b0c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01928459","created_at":"2021-01-18T08:42:47.297Z","updated_at":"2024-07-02T16:36:37.597Z","phase":"Phase 1b","brief_title":"Phase 1b Trial of BGJ398/BYL719 in Solid Tumors","source_id_and_acronym":"NCT01928459","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PIK3CA • FGFR","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • Truseltiq (infigratinib)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 10/01/2013","start_date":" 10/01/2013","primary_txt":" Primary completion: 08/01/2016","primary_completion_date":" 08/01/2016","study_txt":" Completion: 08/01/2016","study_completion_date":" 08/01/2016","last_update_posted":"2020-12-09"},{"id":"1e9e23ff-6f7f-4adf-b6df-acfe8db81bb4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01697605","created_at":"2021-01-18T07:22:41.625Z","updated_at":"2024-07-02T16:36:37.655Z","phase":"Phase 1","brief_title":"A Phase I Study of Oral BGJ398 in Asian Patients","source_id_and_acronym":"NCT01697605","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FGF","pipe":"","alterations":" ","tags":["FGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truseltiq (infigratinib)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 10/19/2012","start_date":" 10/19/2012","primary_txt":" Primary completion: 02/07/2019","primary_completion_date":" 02/07/2019","study_txt":" Completion: 02/07/2019","study_completion_date":" 02/07/2019","last_update_posted":"2020-12-08"},{"id":"bbd1a478-a3ea-4485-aa56-e8b3f93758ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT01975701","created_at":"2021-01-18T08:59:44.203Z","updated_at":"2024-07-02T16:36:52.939Z","phase":"Phase 2","brief_title":"A Phase 2 Study of BGJ398 in Patients With Recurrent GBM","source_id_and_acronym":"NCT01975701","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FGFR2 • FGFR3 • FGFR1 • TACC3 • TACC1","pipe":" | ","alterations":" FGFR2 mutation • FGFR3-TACC3 fusion • FGFR2 fusion • FGFR1 mutation • FGFR1 fusion • FGFR3 fusion • FGFR translocation","tags":["FGFR2 • FGFR3 • FGFR1 • TACC3 • TACC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR3-TACC3 fusion • FGFR2 fusion • FGFR1 mutation • FGFR1 fusion • FGFR3 fusion • FGFR translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truseltiq (infigratinib)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 12/09/2013","start_date":" 12/09/2013","primary_txt":" Primary completion: 10/03/2018","primary_completion_date":" 10/03/2018","study_txt":" Completion: 10/03/2018","study_completion_date":" 10/03/2018","last_update_posted":"2019-12-04"},{"id":"4e06d46a-253b-484d-a0a2-bca662c63ece","acronym":"","url":"https://clinicaltrials.gov/study/NCT01004224","created_at":"2021-01-17T17:13:53.960Z","updated_at":"2024-07-02T16:36:54.872Z","phase":"Phase 1","brief_title":"A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies","source_id_and_acronym":"NCT01004224","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FGFR2 • FGFR3","pipe":" | ","alterations":" FGFR1 amplification • FGFR2 mutation • FGFR2 amplification • FGFR3 mutation • FGFR3 amplification","tags":["FGFR2 • FGFR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 amplification • FGFR2 mutation • FGFR2 amplification • FGFR3 mutation • FGFR3 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truseltiq (infigratinib)"],"overall_status":"Completed","enrollment":" Enrollment 208","initiation":"Initiation: 12/11/2009","start_date":" 12/11/2009","primary_txt":" Primary completion: 10/08/2018","primary_completion_date":" 10/08/2018","study_txt":" Completion: 10/08/2018","study_completion_date":" 10/08/2018","last_update_posted":"2019-10-04"},{"id":"0c646318-e949-4a10-a530-e38a8783b0ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT02575508","created_at":"2021-01-18T12:29:02.575Z","updated_at":"2024-07-02T16:37:31.811Z","phase":"Phase 1/2","brief_title":"Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT02575508","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • Truseltiq (infigratinib) • irinotecan • leucovorin calcium • fluorouracil topical"],"overall_status":"Withdrawn","enrollment":"","initiation":"","start_date":"","primary_txt":" Primary completion: 05/01/2020","primary_completion_date":" 05/01/2020","study_txt":"","study_completion_date":"","last_update_posted":"2016-05-20"}]